glp-1 agonists for weight loss - What is it? Part 2 of a 3-Part

The GLP-1 landscape is expected to broaden significantly, said Dr

Andrianu K, Works D, Christiansen A, Enke C, Chaiken L, Baine M

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Physiologically based pharmacokinetic (PBPK) models have been developed for exenatide (1 of 30), dulaglutide (1 of 30), semaglutide (1 of 30), and tirzepatide (2 of 30)

The most frequently reported include: Nausea Vomiting Diarrhoea Constipation Fatigue Dizziness These effects are usually mild to moderate and tend to improve over time

N Engl J Med 2016;375:183444.ArticlePubMed 36